ATE429645T1 - Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten - Google Patents
Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheitenInfo
- Publication number
- ATE429645T1 ATE429645T1 AT05811604T AT05811604T ATE429645T1 AT E429645 T1 ATE429645 T1 AT E429645T1 AT 05811604 T AT05811604 T AT 05811604T AT 05811604 T AT05811604 T AT 05811604T AT E429645 T1 ATE429645 T1 AT E429645T1
- Authority
- AT
- Austria
- Prior art keywords
- neurodegenerative diseases
- eph receptor
- receptor inhibitors
- treat neurodegenerative
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 108091008815 Eph receptors Proteins 0.000 title abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- VHNYOQKVZQVBLC-RTCGXNAVSA-N (4r,7e,9as)-7-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]-4-(3,4,5-trifluorophenyl)-1,3,4,8,9,9a-hexahydropyrido[2,1-c][1,4]oxazin-6-one Chemical compound C1([C@@H]2COC[C@@H]3CC\C(C(N32)=O)=C/C=2C=C(C(=CC=2)N2C=C(C)N=C2)OC)=CC(F)=C(F)C(F)=C1 VHNYOQKVZQVBLC-RTCGXNAVSA-N 0.000 abstract 1
- 102000050554 Eph Family Receptors Human genes 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 229940124648 γ-Secretase Modulator Drugs 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04028046A EP1662259A1 (de) | 2004-11-25 | 2004-11-25 | Verwendung von Eph Rezeptor-Inhibitoren zur Behandlung von neurodegenerativen Erkrankungen |
| US63059204P | 2004-11-26 | 2004-11-26 | |
| PCT/EP2005/012649 WO2006056467A1 (en) | 2004-11-25 | 2005-11-25 | Use of eph receptor inhibitors for the treatment of neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE429645T1 true ATE429645T1 (de) | 2009-05-15 |
Family
ID=34927535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05811604T ATE429645T1 (de) | 2004-11-25 | 2005-11-25 | Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080213250A1 (de) |
| EP (2) | EP1662259A1 (de) |
| AT (1) | ATE429645T1 (de) |
| CA (1) | CA2589173A1 (de) |
| DE (1) | DE602005014134D1 (de) |
| WO (1) | WO2006056467A1 (de) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006255536A1 (en) * | 2005-06-03 | 2006-12-14 | Novartis Vaccines And Diagnostics Inc. | Methods of treating, diagnosing or detecting cancer using an EphB3 modulator |
| EP2505668A3 (de) | 2006-01-05 | 2013-01-09 | The Ohio State University Research Foundation | Verfahren auf Mikro-RNA-Basis zur Diagnose von Darm-, Lungen- und Bauchspeicheldrüsenkrebs |
| EP2369012A1 (de) | 2006-03-20 | 2011-09-28 | The Ohio State University Research Foundation | Mikro-RNA-Fingerabdrücke während humaner Megakaryozytopoiese |
| ES2318616T3 (es) * | 2006-06-01 | 2009-05-01 | Cellzome Ag | Metodos para la identificacion de moleculas que interactuan con zap-70 y para la purificacion de zap-70. |
| GB0624689D0 (en) * | 2006-12-11 | 2007-01-17 | Glaxo Group Ltd | Novel fluorescent kinase ligands and methods employing the same |
| EP2546651A1 (de) | 2007-03-14 | 2013-01-16 | Bionsil S.r.l. | Modulatorverbindungen der Arzneimittelresistenz in Epitheltumorzellen |
| ATE546543T1 (de) * | 2007-06-08 | 2012-03-15 | Eisai R&D Man Co Ltd | Screening-verfahren mit verwendung des neuen substrats epha4 für gamma-sekretase |
| JPWO2009011426A1 (ja) * | 2007-07-19 | 2010-09-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | γ−セクレターゼの新規基質ｃ−Ｍｅｔを利用したスクリーニング方法 |
| WO2009017234A1 (ja) * | 2007-08-01 | 2009-02-05 | Eisai R & D Management Co., Ltd. | γ-セクレターゼの新規基質c-Retを利用したスクリーニング方法 |
| ES2627059T3 (es) | 2007-08-03 | 2017-07-26 | The Ohio State University Research Foundation | Regiones ultraconservadas que codifican ARNnc |
| CN101836112A (zh) * | 2007-08-22 | 2010-09-15 | 俄亥俄州立大学研究基金会 | 用于在人急性白血病中诱导epha7和erk磷酸化的脱调节的方法和组合物 |
| US8530181B2 (en) * | 2007-11-15 | 2013-09-10 | Eisai R&D Management Co., Ltd. | Method of screening for compounds which affect the cleavage of EphA7 byγ-secretase |
| JP5508857B2 (ja) * | 2007-11-30 | 2014-06-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 新規活性を有するＥｐｈＡ４ポリペプチドおよびその用途 |
| US20100113415A1 (en) * | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| US20100197688A1 (en) * | 2008-05-29 | 2010-08-05 | Nantermet Philippe G | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| WO2009150513A2 (en) * | 2008-06-09 | 2009-12-17 | Oxford Biotherapeutics Ltd. | Protein |
| US20100256214A1 (en) * | 2009-04-02 | 2010-10-07 | Burnham Institute For Medical Research | Eph receptor ligands and methods of use |
| WO2010141974A1 (en) * | 2009-06-10 | 2010-12-16 | The University Of Melbourne | Therapeutic applications |
| US8159780B2 (en) | 2009-07-15 | 2012-04-17 | Seagate Technology Llc | Recording head heater systems with two electrical connections |
| JP2013506687A (ja) | 2009-09-30 | 2013-02-28 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | オートファジー促進遺伝子産物の変調によりオートファジーを変調する方法 |
| AU2011326032B2 (en) | 2010-11-12 | 2016-10-06 | The Ohio State University Research Foundation | Materials and methods related to microRNA-21, mismatch repair, and colorectal cancer |
| EP2640368B1 (de) | 2010-11-15 | 2020-12-30 | The Ohio State University Research Foundation | Mukoadhäsive systeme mit kontrollierter freisetzung |
| US9101644B2 (en) | 2010-11-15 | 2015-08-11 | The J. David Gladstone Institutes | Methods of treating neurodegenerative disease |
| DK2653552T3 (en) | 2010-12-17 | 2017-01-16 | Eisai R&D Man Co Ltd | SCREENING METHOD USING GELATINASE-MEDIATED EphA4 DIVISION REACTION AS INDICATOR |
| US9784751B2 (en) | 2011-04-25 | 2017-10-10 | Eisai R&D Management Co., Ltd. | Method for detecting neurological disease associated with cognitive impairment by measuring EphA4 extracellular domain |
| JP2014530612A (ja) | 2011-10-14 | 2014-11-20 | ジ・オハイオ・ステート・ユニバーシティ | 卵巣がんに関する方法および材料 |
| AU2012352265B2 (en) | 2011-12-13 | 2017-02-16 | Ohio State Innovation Foundation | Methods and compositions related to miR-21 and miR-29a, exosome inhibition, and cancer metastasis |
| WO2013110053A1 (en) | 2012-01-20 | 2013-07-25 | The Ohio State University | Breast cancer biomarker signatures for invasiveness and prognosis |
| AR105938A1 (es) * | 2015-09-08 | 2017-11-22 | Eisai R&D Man Co Ltd | Anticuerpo anti-epha4 |
| MY207780A (en) | 2019-07-01 | 2025-03-18 | Eisai R&D Man Co Ltd | Anti-epha4 antibody |
| EP4436999A4 (de) * | 2021-11-22 | 2025-10-22 | Univ China Medical | Mono- oder multispezifischer antikörper gegen ephrin-typ-a-rezeptor 10, chimäre antigenrezeptor-t-zelle, die diesen exprimiert, und verwendungen davon |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1057484A4 (de) * | 1998-02-23 | 2002-11-20 | Sagami Chem Res | Inhibitoren des zelltodes |
| GB9828640D0 (en) * | 1998-12-23 | 1999-02-17 | Smithkline Beecham Plc | Novel method and compounds |
| AU2003206397B2 (en) * | 2002-01-04 | 2008-07-17 | The Rockefeller University | Compositions and methods for prevention and treatment of amyloid-beta peptide-related disorders |
| AU2003238874A1 (en) * | 2002-06-05 | 2003-12-22 | Janssen Pharmaceutica N.V. | Bisindolyl-maleimid derivatives as kinase inhibitors |
| WO2004028551A1 (en) * | 2002-09-24 | 2004-04-08 | The Burnham Institute | Novel agents that modulate eph receptor activity |
-
2004
- 2004-11-25 EP EP04028046A patent/EP1662259A1/de not_active Withdrawn
-
2005
- 2005-11-25 US US11/791,289 patent/US20080213250A1/en not_active Abandoned
- 2005-11-25 DE DE602005014134T patent/DE602005014134D1/de not_active Expired - Fee Related
- 2005-11-25 WO PCT/EP2005/012649 patent/WO2006056467A1/en not_active Ceased
- 2005-11-25 EP EP05811604A patent/EP1815255B1/de not_active Expired - Lifetime
- 2005-11-25 CA CA002589173A patent/CA2589173A1/en not_active Abandoned
- 2005-11-25 AT AT05811604T patent/ATE429645T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1815255B1 (de) | 2009-04-22 |
| US20080213250A1 (en) | 2008-09-04 |
| WO2006056467A1 (en) | 2006-06-01 |
| EP1815255A1 (de) | 2007-08-08 |
| DE602005014134D1 (de) | 2009-06-04 |
| CA2589173A1 (en) | 2006-06-01 |
| EP1662259A1 (de) | 2006-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE429645T1 (de) | Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten | |
| MX2010002674A (es) | Moduladores de gamma secretasa. | |
| ATE399155T1 (de) | Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen | |
| EA200970403A1 (ru) | Бициклические триазолы в качестве модуляторов протеинкиназы | |
| ATE544748T1 (de) | Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen | |
| MX2010006379A (es) | Moduladores de la secretasa gamma. | |
| ATE512663T1 (de) | Kombination zur behandlung von erkrankungen mit zellproliferation | |
| MX2010005028A (es) | Moduladores de gamma secretasa. | |
| DE602006019560D1 (de) | 2-cyanobenzolsulfonamidverbindungen zur behandlung von samen | |
| ATE414089T1 (de) | Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust | |
| EA200900802A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| TNSN07027A1 (en) | Pyrrolo-pyridine kinase modulators | |
| EA200600078A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| MX2008006076A (es) | Metodos, composiciones y kits para el tratamiento de condiciones medicas. | |
| NO20071272L (no) | Modulatorer av muskarine reseptorer. | |
| ATE512948T1 (de) | Biphenyl-sulfonyl- und phenyl-heteroaryl-sulfonyl-modulatoren des histamin-h3-rezeptors zur behandlung von damit verbundenen erkrankungen | |
| EP1732484A4 (de) | Ophthalmisches implantat zur behandlung von glaukom | |
| EA202091559A1 (ru) | Способ получения модуляторов соматостатина | |
| ATE525372T1 (de) | Pyrazinderivate als natriumkanalmodulatoren zur behandlung von schmerzen | |
| ATE542536T1 (de) | 3-ä4-(dibenzoäb,füä1,4üoxazepin-11-yl)-piperazi - 1-ylü-2,2-dimethyl propansäure zur verwendung in der behandlung von schlafstörungen | |
| ATE421501T1 (de) | 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck | |
| NO20073369L (no) | Modulatorer av muskarinreseptorer | |
| DE602004022035D1 (de) | Verwendung von pthalide derivativen zur behandlung | |
| ATE423110T1 (de) | Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen | |
| EP4149464A4 (de) | Thiolhaltige verbindungen zur verwendung bei der behandlung von coronavirus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |